Pipeline | Field | Target | Development Phase |
---|---|---|---|
|
|||
Lurasidone | CNS | Schizophrenia and bipolar disorder |
|
JM-010 (Contera) |
CNS | Dyskinesia in Parkinson’s disease |
|
SOL-804 (Dyna) |
Oncology (Innovative Formulation) |
Metastatic castration resistant prostate cancer |
|
AhR Inhibitor (JaguAhr) |
Immuno- Oncology |
Solid tumors |
|
PKR Inhibitor (Protekt) |
CNS | Neurodegenerative disorders |
|
PD Program | CNS | Parkinson’s disease |
|